Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain. …
Lateral Pharma secures key U.S. patent for novel neuropathic pain therapy
March 9, 2026 Australian Biotech
Latest Video
New Stories
-
An exchange that reveals the truth of a review that has now become a lot like 'Weekend at Bernie's'
June 3, 2026 - - Latest News -
Patient voices take centre stage at the 2026 Patient's Choice Awards
June 3, 2026 - - Latest News -
Officials confirm shift in Budget management of underspends
June 3, 2026 - - Latest News -
Invitation confusion clouds Delphi studies and captures medical device sector
June 3, 2026 - - Latest News -
Omico opens a new chapter in precision oncology research
June 1, 2026 - - Latest News -
Ex-MA executive named the first CEO of Medicinal Cannabis Council Australia
June 1, 2026 - - Latest News -
Oral RAS inhibitor doubles median survival and cuts death risk in metastatic pancreatic cancer
June 1, 2026 - - Latest News